Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Applied Genetic Technologies Corporation is a biotechnology business based in the US. Applied Genetic Technologies Corporation shares (AGTC) are listed on the NASDAQ and all prices are listed in US Dollars. Applied Genetic Technologies Corporation employs 83 staff and has a trailing 12-month revenue of around USD$2.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$4.09 |
---|---|
52-week range | USD$2.29 - USD$8.63 |
50-day moving average | USD$4.6497 |
200-day moving average | USD$5.2865 |
Wall St. target price | USD$14.81 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.11 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.09 from 2020-12-31
1 week (2021-01-08) | -9.91% |
---|---|
1 month (2020-12-16) | -13.35% |
3 months (2020-10-15) | -23.69% |
6 months (2020-07-15) | -29.48% |
1 year (2020-01-15) | -49.94% |
---|---|
2 years (2019-01-15) | 30.25% |
3 years (2018-01-12) | 4.2 |
5 years (2016-01-15) | 15.55 |
Revenue TTM | USD$2.5 million |
---|---|
Gross profit TTM | USD$-13,933,000 |
Return on assets TTM | -36.72% |
Return on equity TTM | -80.04% |
Profit margin | 0% |
Book value | $2.173 |
Market capitalisation | USD$118.8 million |
TTM: trailing 12 months
There are currently 1.0 million Applied Genetic Technologies Corporation shares held short by investors – that's known as Applied Genetic Technologies Corporation's "short interest". This figure is 11% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Applied Genetic Technologies Corporation shares can be evaluated.
Applied Genetic Technologies Corporation's "short interest ratio" (SIR) is the quantity of Applied Genetic Technologies Corporation shares currently shorted divided by the average quantity of Applied Genetic Technologies Corporation shares traded daily (recently around 462640.27149321). Applied Genetic Technologies Corporation's SIR currently stands at 2.21. In other words for every 100,000 Applied Genetic Technologies Corporation shares traded daily on the market, roughly 2210 shares are currently held short.
However Applied Genetic Technologies Corporation's short interest can also be evaluated against the total number of Applied Genetic Technologies Corporation shares, or, against the total number of tradable Applied Genetic Technologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Applied Genetic Technologies Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Applied Genetic Technologies Corporation shares in existence, roughly 40 shares are currently held short) or 0.0397% of the tradable shares (for every 100,000 tradable Applied Genetic Technologies Corporation shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Applied Genetic Technologies Corporation.
Find out more about how you can short Applied Genetic Technologies Corporation stock.
We're not expecting Applied Genetic Technologies Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Applied Genetic Technologies Corporation's shares have ranged in value from as little as $2.29 up to $8.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Applied Genetic Technologies Corporation's is 2.3008. This would suggest that Applied Genetic Technologies Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.